-DOCSTART- -X- O
The -X- _ O
human -X- _ O
papillomavirus -X- _ O
( -X- _ O
HPV -X- _ O
) -X- _ O
vaccines -X- _ O
consist -X- _ O
of -X- _ O
major -X- _ B-Intervention
capsid -X- _ I-Intervention
protein -X- _ I-Intervention
( -X- _ I-Intervention
L1 -X- _ I-Intervention
) -X- _ I-Intervention
virus-like -X- _ I-Intervention
particles -X- _ I-Intervention
( -X- _ I-Intervention
VLP -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
are -X- _ O
highly -X- _ O
efficacious -X- _ O
against -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
cervical -X- _ O
cancer -X- _ O
precursors -X- _ O
attributable -X- _ O
to -X- _ O
oncogenic -X- _ O
genotypes -X- _ O
, -X- _ O
HPV16 -X- _ O
and -X- _ O
HPV18. -X- _ O
A -X- _ O
degree -X- _ O
of -X- _ O
vaccine-induced -X- _ O
cross- -X- _ O
protection -X- _ O
has -X- _ O
also -X- _ O
been -X- _ O
demonstrated -X- _ B-Outcome
against -X- _ I-Outcome
genetically-related -X- _ I-Outcome
genotypes -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
Alpha-7 -X- _ I-Outcome
( -X- _ I-Outcome
HPV18-like -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
Alpha-9 -X- _ I-Outcome
( -X- _ I-Outcome
HPV16-like -X- _ I-Outcome
) -X- _ I-Outcome
species -X- _ I-Outcome
groups -X- _ I-Outcome
which -X- _ I-Outcome
is -X- _ I-Outcome
coincident -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
detection -X- _ I-Outcome
of -X- _ I-Outcome
L1 -X- _ I-Outcome
cross-neutralising -X- _ I-Outcome
antibodies. -X- _ I-Outcome
In -X- _ O
this -X- _ O
study -X- _ O
the -X- _ O
L1 -X- _ O
domains -X- _ O
recognised -X- _ O
by -X- _ O
inter-genotype -X- _ O
cross- -X- _ O
neutralising -X- _ O
antibodies -X- _ O
were -X- _ O
delineated. -X- _ O
L1 -X- _ B-Outcome
crystallographic -X- _ I-Outcome
homology -X- _ I-Outcome
models -X- _ I-Outcome
predicted -X- _ I-Outcome
a -X- _ I-Outcome
degree -X- _ I-Outcome
of -X- _ I-Outcome
structural -X- _ I-Outcome
diversity -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
L1 -X- _ I-Outcome
loops -X- _ I-Outcome
of -X- _ I-Outcome
HPV16 -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
non-vaccine -X- _ I-Outcome
Alpha-9 -X- _ I-Outcome
genotypes. -X- _ I-Outcome
These -X- _ O
structural -X- _ O
predictions -X- _ O
informed -X- _ O
the -X- _ O
design -X- _ O
of -X- _ O
chimeric -X- _ O
pseudovirions -X- _ O
with -X- _ O
inter-genotype -X- _ O
loop -X- _ O
swaps -X- _ O
which -X- _ O
demonstrated -X- _ O
that -X- _ O
the -X- _ O
L1 -X- _ B-Outcome
domains -X- _ I-Outcome
recognised -X- _ I-Outcome
by -X- _ I-Outcome
inter-genotype -X- _ I-Outcome
cross- -X- _ I-Outcome
neutralising -X- _ I-Outcome
antibodies -X- _ I-Outcome
comprise -X- _ I-Outcome
residues -X- _ I-Outcome
within -X- _ I-Outcome
the -X- _ I-Outcome
DE -X- _ I-Outcome
loop -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
late -X- _ I-Outcome
region -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
FG -X- _ I-Outcome
loop. -X- _ I-Outcome
These -X- _ O
data -X- _ O
contribute -X- _ O
to -X- _ O
our -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
L1 -X- _ B-Outcome
domains -X- _ I-Outcome
recognised -X- _ I-Outcome
by -X- _ I-Outcome
vaccine-induced -X- _ I-Outcome
cross-neutralising -X- _ I-Outcome
antibodies. -X- _ I-Outcome
Such -X- _ O
specificities -X- _ O
may -X- _ O
play -X- _ O
a -X- _ O
critical -X- _ O
role -X- _ O
in -X- _ O
vaccine-induced -X- _ O
cross- -X- _ O
protection -X- _ O
. -X- _ O

